Current:Home > InvestHow an abortion pill ruling could threaten the FDA's regulatory authority-LoTradeCoin
How an abortion pill ruling could threaten the FDA's regulatory authority
View Date:2024-12-24 07:16:54
Two contradictory court rulings are raising questions not only about the future of the abortion pill mifepristone, but the federal government's authority to approve and regulate drugs in general.
Mifepristone is widely used across the U.S. to end pregnancy in the first 10 weeks of gestation and help manage miscarriages. The Food and Drug Administration (FDA) first approved it in 2000, after it evaluated data and concluded the drug's health benefits outweigh its risks.
More than two decades later, a federal judge in Texas refuted the FDA's approval, issuing an injunction that would suspend its approval nationwide. That pause is set to take effect on Friday, though the Justice Department has appealed to block it.
In Washington state on Friday, a different federal judge issued a separate ruling that prohibits the FDA from pulling the drug from the market.
Judges' decisions heighten uncertainty
Uncertain about the future of mifepristone access, several states began stockpiling doses of the drug, major pharmaceutical companies expressed support for the FDA, and some Democrats and at least one Republican lawmaker urged the Biden administration to ignore the Texas ruling (a suggestion the White House dismissed as a potentially "dangerous precedent").
Holly Fernandez Lynch, an assistant professor of medical ethics and law at the University of Pennsylvania, calls the Texas ruling "truly an unprecedented decision."
She tells Morning Edition's Michel Martin that pharmaceutical companies that develop new products typically conduct clinical trials, evaluate drugs' safety and effectiveness, and submit a "massive dossier of data" to the FDA, the agency given authority by Congress to determine which products can go to market.
"What has happened in this case from the Northern District of Texas is that we have a single federal judge who has inserted himself, standing in for the agency to say FDA should have never approved mifepristone because they did not have adequate data to determine that it was safe," Fernandez Lynch says.
Plaintiffs revive questions, despite safety history
Fernandez Lynch says more than 100 studies over 30 years affirm the safety of mifepristone, which the FDA has evaluated multiple times over the decades (including approving a generic version in 2019).
But in November 2022, months after the Supreme Court overturned the federal abortion protections of Roe v. Wade, a coalition of anti-abortion doctors and groups filed a lawsuit seeking to undo the drug's approval, reviving an earlier attempt that had been denied in 2016.
Fernandez Lynch says the plaintiffs "cherry picked" a couple of those studies to make their argument.
"There was no new evidence that was presented to the court that would change FDA's determination about whether this product meets the statutory standard for approval," she adds. "What changed in this case was that ultimately the litigants were able to get their arguments in front of a federal judge."
What does it mean for the drug approval process?
Former FDA Commissioner Jane Henney, who led the agency in 2000 when mifepristone was first approved, disputes allegations that its approval was improperly fast-tracked.
"I can assure you that mifepristone was handled in a very proper way. It was given a very thorough review. It was not rushed," she told NPR's Juana Summers in an interview for All Things Considered on Tuesday.
She acknowledges that the mifepristone was approved under a section of the law that provides for an accelerated process, but denies that safety was compromised.
"The approval process, in terms of looking at all the scientific data, all of the clinical data, the data around how this drug was manufactured followed the normal process of how the FDA reviews every product that it has," Henney says.
Fernandez Lynch says if judges can weigh in on drug approvals, the pharmaceutical industry could choose to "stick to things that aren't going to ruffle any feathers."
"What may happen, if this decision is allowed to stand, is that the industry is going to think, 'Hmm, maybe we shouldn't spend our resources on drugs that could be controversial, that might cause people to take us to court to say that FDA was wrong in approving this drug,'" Fernandez Lynch says.
Henney also says the Texas ruling is "disappointing" because it not only sends a "very chaotic" message to people seeking abortion care, but could call into question the validity of the FDA process, what she calls the "gold standard" for the U.S. and the world.
"If that is disrupted, it really causes chaos not just in the marketplace, but chaos for medical providers and patients who need a sound and solid voice of authority to say this has been reviewed, these products are safe and effective," says Henney.
Olivia Hampton edited the audio version of the Hernandez Lynch interview. Jan Johnson edited this digital story.
veryGood! (8)
Related
- Footage shows Oklahoma officer throwing 70-year-old to the ground after traffic ticket
- Former Indiana lawmaker pleads guilty to casino corruption charge
- Why Coco Austin Is Happy/Sad as Her and Ice-T's Daughter Chanel Turns 8
- Chicago Blackhawks move to cut veteran Corey Perry for engaging in 'unacceptable' conduct
- Incredible animal moments: Watch farmer miraculously revive ailing chick, doctor saves shelter dogs
- 5-year-old girl, man swept out by California wave identified as granddaughter, grandfather
- LGBTQ+ rights group sues over Iowa law banning school library books, gender identity discussion
- Michigan man accused of keeping dead wife in freezer sentenced to up to 8 years in prison
- Ariana Grande's Brunette Hair Transformation Is a Callback to Her Roots
- 1000-Lb. Sisters’ Amy Slaton Debuts New Romance After Michael Halterman Breakup
Ranking
- Suspect arrested after deadly Tuskegee University homecoming shooting
- Kansas unveiled a new blue and gold license plate. People hated it and now it’s back to square 1
- Margaret Huntley Main, the oldest living Tournament of Roses queen, dies at 102
- 3 climate impacts the U.S. will see if warming goes beyond 1.5 degrees
- 'Serial swatter': 18-year-old pleads guilty to making nearly 400 bomb threats, mass shooting calls
- The Best TikTok Gifts for Teens They’ll Actually Love and Want
- Michael Douglas gets lifetime achievement award at International Film Festival of India in Goa
- Banker involved in big loans to Trump’s company testifies for his defense in civil fraud trial
Recommendation
-
Utah AD Mark Harlan rips officials following loss to BYU, claims game was 'stolen from us'
-
Host of upcoming COP28 climate summit UAE planned to use talks to make oil deals, BBC reports
-
Cardiologist runs half-marathon with runners whose lives he saved a year ago
-
A judge awards Aretha Franklin's properties to her sons, citing a handwritten will
-
Burger King is giving away a million Whoppers for $1: Here's how to get one
-
Antonio Gates, Julius Peppers among semifinalists for 2024 Pro Football Hall of Fame class
-
Emirati-designated COP28 leader forcefully denies report UAE wanted to seek oil deals in summit
-
Rapper Young Thug’s trial on racketeering conspiracy and gang charges begins in Atlanta